Pharma R&D Pipeline Value Jumps 18% to $493 Billion, Drug Sales Forecast to Grow Nearly 5% Annually
Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the US and Europe, fueling a projected 5% increase in global prescription sales over the next 5 years according to the “EvaluatePharma World Preview 2015, Outlook to 2020” report from life science market intelligence firm Evaluate Ltd. With the FDA approving an unprecedented 50 drugs in 2014, eight of which are forecast to have sales of more than $1 billion 5 years after launch, sustained R&D productivity may finally be within reach.
“Any fears that the pharmaceutical industry might be heading towards a slowdown after the last 2 years of phenomenal growth can be put to rest for now,” said Lisa Urquhart, Editor of EP Vantage, the editorial arm of Evaluate. “However, for the industry to sustain this impressive growth they will have to make compromises around global pricing and market access. As such, pharmaceutical companies need to either accept lower prices for its products, or persuade payers that the therapeutic benefits outweigh the cost of disease.”
World Preview 2015 Highlights:
• Worldwide prescription drug sales to reach nearly one trillion dollars by 2020 with a CAGR of 4.8% between 2014 and 2020
• 2014 US prescription drug sales surge 8.9%; Europe returns to growth with a 2.4% jump while Japanese sales in yen dropped by 2.6%
• R&D pipeline values increase to $492.8 billion from $418.5 billion in 2014; Gilead’s potential new combination hepatitis C product valued highest at $24.8 billion
• Humira remained the top-selling product in 2014 with sales of $13.9 billion; Sovaldi debuts at number two with sales of $10 billion
• FDA approves record-breaking 50 new drugs in 2014 with a 43% increase in 5-year post-launch sales potential; Bristol-Myers Squibb’s Opdivo was the number one approval
• Novartis will remain the number one pharmaceutical company through 2020 with total prescription drug sales of $53.3 billion
• Value of M&A transactions almost doubled to $116 billion in 2014; value of venture financing deals leapt 36% to $8.2 billion.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance